Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Risk Reduction Behavior × Tamoxifen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 232 Carcinoma, Intraductal, Noninfiltrating 20 Breast Carcinoma In Situ 16 Neoplasm Metastasis 13 Neoplasms 11 Breast Neoplasms, Male 11 Ovarian Neoplasms 8 Inflammatory Breast Neoplasms 6 Glioblastoma 5 Endometrial Neoplasms 4 Central Nervous System Neoplasms 4 Prostatic Neoplasms 3 Obesity 3 Gliosarcoma 3 Fallopian Tube Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Breast Cancer Female 3 Brain Neoplasms 3 Urinary Bladder Neoplasms 2 Sleep Wake Disorders 2 Recurrence 2 Multiple Endocrine Neoplasia Type 1 2 Hot Flashes 2 Glioma 2 Fibroadenoma 2 ER+ Breast Cancer 2 Carcinoma, Lobular 2 Carcinoma, Ductal, Breast 2 Astrocytoma 2 Vitamin D Deficiency 1

Interventions

College Fraternities and Sororities 2 bazedoxifene 1 Tamoxifen 1 Risk Assessment 1 Radon 1 Price Transparency 1 Nutrition Assessment 1 Exercise 1 Estrogens, Conjugated (USP) 1 Counseling 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03346200 2025-03-07

KARISMA2

Karolinska Institutet

Phase 2 Completed

1,440 enrolled 14 charts

Breast Neoplasms, Risk Reduction Behavior

Data powered by HemOnc (CC BY 4.0) Colophon ⚡